Search Results
Aug 06, 2026, 10:31 ET The Next Billion-Dollar Opportunity in Alzheimer's Disease Market: 6 Pipeline Therapies to Watch | DelveInsight
emerging late-stage therapies poised to enter the Alzheimer's disease therapeutics market.Suven Life Sciences' Masupirdine5-HT6 antagonistMasupirdine (SUVN-502) is an investigational small-molecule candidate from Suven Life Sciences that is being developed
More news about: DelveInsight Business Research, LLP
Aug 03, 2026, 16:05 ET MATSON, INC. ANNOUNCES SECOND QUARTER 2026 RESULTS AND RAISES FULL YEAR OUTLOOK
Time:4:30 p.m. ET / 1:30 p.m. PT / 10:30 a.m. HTThe conference call will be broadcast live along with an additional slide presentation on the Company's website at
More news about: Matson, Inc.
Aug 03, 2026, 10:31 ET Dementia-related Psychosis Market Gearing Up for Outstanding Expansion at a CAGR of 26.2% During the Forecast Period (2026-2036) | DelveInsight
DRP treatment, offering a specialized approach for patients with Parkinson's, Alzheimer's, and Lewy Body-related psychosis. By selectively targeting 5-HT2A receptors without blocking dopamine, it addresses the urgent need for a therapy that treats psychotic symptoms while preserving motor stability.Advancements
More news about: DelveInsight Business Research, LLP
Jul 30, 2026, 08:19 ET Rocket One and NASA Reach Agreement to Advance Space AI Technology
pursue opportunities in nano-launch systems and nanosatellite deployment. The Company's biotechnology pipeline, including, but not limited to, HT-001, HT-KIT, HT-ALZ, and its GDNF-based metabolic program, will continue to be advanced under a wholly owned subsidiary.Forward-Looking StatementsThis
More news about: Rocket One Inc.
Jul 24, 2026, 09:06 ET ELEGOO Launches H1 HT Filament Dryer: Up to 85°C High-Temp Drying for High-Quality 3D Prints
dryer, the H1 HT Filament Dryer. Reaching an exceptional drying temperature of up to 85°C, the device tackles moisture-related print failures at their source to elevate overall print quality, while offering open compatibility with virtually all FDM 3D printers on the market. With the H1 HT, ELEGOO's FDM
More news about: Elegoo
Jul 24, 2026, 09:06 ET ELEGOO Launches H1 HT Filament Dryer: Up to 85°C High-Temp Drying for High-Quality 3D Prints
dryer, the H1 HT Filament Dryer. Reaching an exceptional drying temperature of up to 85°C, the device tackles moisture-related print failures at their source to elevate overall print quality, while offering open compatibility with virtually all FDM 3D printers on the market. With the H1 HT, ELEGOO's FDM
More news about: Elegoo
Jul 24, 2026, 09:06 ET ELEGOO bringt den Filamenttrockner H1 HT auf den Markt: Hochtemperaturtrocknung bis 85 °C für hochwertige 3D-Drucke
ELEGOO, eine aufstrebende Marke im Bereich der globalen intelligenten Fertigung, hat heute die Einführung seines allerersten Filamenttrockners, des H1 HT, bekannt gegeben. Mit einer außergewöhnlichen Trocknungstemperatur von bis zu 85 °C bekämpft das Gerät feuchtigkeitsbedingte Druckfehler an der Quelle
More news about: Elegoo
Jul 24, 2026, 09:06 ET ELEGOO lanza el secador de filamentos H1 HT
- ELEGOO lanza el secador de filamentos H1 HT: Secado a alta temperatura de hasta 85°C para impresiones 3D de alta calidadSHENZHEN, China, 24 de julio de 2026 /PRNewswire/ -- ELEGOO, una marca en rápido crecimiento
More news about: Elegoo
Jul 24, 2026, 09:06 ET ELEGOO lance le sécheur de filaments H1 HT : séchage à haute température (jusqu'à 85 °C) pour des impressions 3D de haute qualité
plein essor dans le secteur mondial de la fabrication intelligente, a annoncé aujourd'hui le lancement de son tout premier sécheur de filaments, le H1 HT. Atteignant une température de séchage exceptionnelle pouvant aller jusqu'à 85 °C, cet appareil s'attaque aux défauts d'impression liés à l'humidité afin
More news about: Elegoo
Jul 21, 2026, 10:31 ET Acute Pain Market Forecast Signals Accelerated Growth at a CAGR of 12% During the Forecast Period (2026-2036), Driven by Novel Non-Opioid Therapies and Expanding Treatment Options | DelveInsight
(mdc-CWM), NTM-001, Cebranopadol, Meloxicam (MR-107A-02), XG005, TLC590, Naltrexone and acetaminophen (DEPADE), LTG-001, Vocacapsaicin (CA-008), ATX101, HT-6184, Esflurbiprofen transdermal (TK-254Rx), CT001, Alenura (VNX001), BHV-2100, and others.Discover what is the future of the acute pain
More news about: DelveInsight Business Research, LLP
Jul 21, 2026, 08:17 ET Rocket One Expands AI Infrastructure Platform Through Strategic Partnership with Placeve to Advance Defense, Space, and Intelligent Edge Computing
pursue opportunities in nano-launch systems and nanosatellite deployment. The Company's biotechnology pipeline, including, but not limited to, HT-001, HT-KIT, HT-ALZ, and its GDNF-based metabolic program, will continue to be advanced under a wholly owned subsidiary.About Placeve Inc.Placeve
More news about: Rocket One Inc.
Jul 20, 2026, 03:46 ET Lundbeck announces last patient randomized in DEEp OCEAN, a large Phase III trial in developmental and epileptic encephalopathies (DEEs)
DEE.About bexicaserinBexicaserin is an investigational, oral, highly selective superagonist of the 5-HT2C receptor subtype.3 Through its unique and selective binding to 5-HT2C, the potential for adverse effects linked with other receptor subtypes may be minimized. Bexicaserin acts via
More news about: H. Lundbeck A/S
Jul 20, 2026, 03:42 ET Lundbeck announces last patient randomized in DEEp OCEAN, a large Phase III trial in developmental and epileptic encephalopathies (DEEs)
DEE.About bexicaserinBexicaserin is an investigational, oral, highly selective superagonist of the 5-HT2C receptor subtype.3 Through its unique and selective binding to 5-HT2C, the potential for adverse effects linked with other receptor subtypes may be minimized. Bexicaserin acts via
More news about: H. Lundbeck A/S
Jul 16, 2026, 06:45 ET Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
VLS-01 and EMP-01 are in Phase 2 clinical development. The Company is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists. These programs aim to create breakthroughs in mental health through transformative interventional psychiatry therapies that can integrate
More news about: Eli Lilly and Company
Jul 15, 2026, 17:13 ET MATSON ANNOUNCES PRELIMINARY 2Q26 RESULTS, PROVIDES BUSINESS UPDATE AND ANNOUNCES 2Q26 EARNINGS CALL DATE
Time:4:30 p.m. ET / 1:30 p.m. PT / 10:30 a.m. HTThe conference call will be broadcast live along with an additional slide presentation on the Company's website at
More news about: Matson, Inc.
Jul 13, 2026, 08:30 ET Tomocube Launches HT-T1 Desktop for 3D Glass Substrate Defect Analysis in Advanced Packaging
July 13, 2026 /PRNewswire/ -- Tomocube, a 3D non-destructive inspection and metrology company, today announced the launch of HT-T1 Desktop (HT-T1D), a desktop holotomography system for high-resolution 3D defect analysis of glass substrates used in next-generation semiconductor packaging.
More news about: Tomocube
Jul 13, 2026, 08:15 ET Halia Therapeutics Presents Two AAIC 2026 Posters on HT-4253 for Alzheimer's Prevention in APOE4 Carriers
pathology. Eligible participants enroll in a 48-week study of once-daily HT-4253, tracking blood-based biomarkers to assess whether it can alter disease onset and progression.ABOUT HT-4253 AND THE LRRK2–RAB10 PATHWAYHT-4253 is a brain-penetrant, small molecule inhibitor of leucine-rich
More news about: Halia Therapeutics
Jul 13, 2026, 03:30 ET Tomocube Launches HT-T1 Desktop for 3D Glass Substrate Defect Analysis in Advanced Packaging
July 13, 2026 /PRNewswire/ -- Tomocube, a 3D non-destructive inspection and metrology company, today announced the launch of HT-T1 Desktop (HT-T1D), a desktop holotomography system for high-resolution 3D defect analysis of glass substrates used in next-generation semiconductor packaging.
More news about: Tomocube
Jul 13, 2026, 03:30 ET Tomocube präsentiert HT-T1 Desktop für die 3D-Defektanalyse von Glassubstraten im Advanced Packaging
/PRNewswire/ -- Tomocube, ein führendes Unternehmen für zerstörungsfreie 3D-Inspektion und Messtechnik, gab heute die Markteinführung des HT-T1 Desktop (HT-T1D) bekannt. Dabei handelt es sich um ein kompaktes Holotomographie-System für die hochauflösende 3D-Defektanalyse von Glassubstraten, die im Halbleiter-Packaging
More news about: Tomocube
Jul 13, 2026, 03:30 ET Tomocube lance le HT-T1 Desktop pour l'analyse 3D des défauts des substrats de verre dans le conditionnement avancé
2026 /PRNewswire/ -- Tomocube, un leader de l'inspection non destructive et de la métrologie 3D, a annoncé aujourd'hui le lancement du HT-T1 Desktop (HT-T1D). Ce système d'holotomographie de bureau est conçu pour l'analyse 3D haute résolution des défauts des substrats de verre utilisés dans le conditionnement
More news about: Tomocube
Jul 13, 2026, 03:30 ET Tomocube lanza el HT-T1 Desktop para el análisis de defectos en 3D de sustratos de vidrio en el empaquetado Avanzado
2026 /PRNewswire/ -- Tomocube, empresa líder en metrología e inspección no destructiva en 3D, ha anunciado hoy el lanzamiento del HT-T1 Desktop (HT-T1D). Se trata de un sistema de holotomografía de escritorio diseñado para el análisis de defectos en 3D de alta resolución en sustratos
More news about: Tomocube
Jul 09, 2026, 08:18 ET Rocket One Adds SpaceXAI API to Its AI Technology Stack, Advancing Next-Generation Space and Defense Computing
pursue opportunities in nano-launch systems and nanosatellite deployment. The Company's biotechnology pipeline, including, but not limited to, HT-001, HT-KIT, HT-ALZ, and its GDNF-based metabolic program, will continue to be advanced under a wholly owned subsidiary.Forward-Looking StatementsThis
More news about: Rocket One Inc.
Jul 08, 2026, 17:47 ET As FIFA World Cup Fever Sweeps North America, Soccer Players Need Rest
TRPV-1 receptors, CBD can help moderate both the perception of discomfort and body temperature. Higher concentrations of CBD can activate the body's 5-HT1A serotonin receptors, and help release one of the body's feel-good chemicals. Anxiety over upcoming matches and jet lag can seriously interfere with
More news about: Fusion CBD Products
Jun 30, 2026, 13:59 ET $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of LCI Industries (NYSE: LCII)
https://monteverdelaw.com/case/lci-industries/https://monteverdelaw.com/case/psb-holdings-inc/https://monteverdelaw.com/case/xoma-royalty-corporation/https://monteverdelaw.com/case/globalstar-inc-2/https://monteverdelaw.com/case/calisa-acquisition-corp/https://monteverdelaw.com/?post_type=case&p=12170&preview=true.
More news about: Monteverde & Associates PC
Jun 30, 2026, 08:33 ET Horvath & Tremblay Acquires SCOPE, Expanding its National CRE Platform Deeper into the Mid-Atlantic
involved."— Phil Sharrow, Founder & President, SCOPE A PLATFORM BUILT FOR GROWTHHorvath & Tremblay "HT" has established itself as one of the most dynamic growth stories in commercial real estate. It currently serves private investors and institutions
More news about: Horvath & Tremblay